Heroism in the Face of the COVID-19 Pandemic

Robert O. Bonow; Ajay J. Kirtane; Roxana Mehran; Ann Marie Navar

doi:10.1001/jamacardio.2020.2493

Heroism in the Face of the COVID-19 Pandemic

Robert O. Bonow, Ajay J. Kirtane, Roxana Mehran, Ann Marie Navar

Research output: Contribution to journal › Editorial

Original language	English
Pages (from-to)	1163-1164
Number of pages	2
Journal	JAMA Cardiology
Volume	5
Issue number	10
DOIs	https://doi.org/10.1001/jamacardio.2020.2493
State	Published - Oct 2020

Access to Document

10.1001/jamacardio.2020.2493

Cite this

@article{d4a7cd7601ea486d82cbb7e17d75d976,

title = "Heroism in the Face of the COVID-19 Pandemic",

author = "Bonow, \{Robert O.\} and Kirtane, \{Ajay J.\} and Roxana Mehran and Navar, \{Ann Marie\}",

note = "Funding Information: reported receiving institutional funding to Columbia University and/or the Cardiovascular Research Foundation for research, speaking engagements, and/or consulting from Medtronic plc, Boston Scientific Corporation, Abbott Vascular, Abiomed, CSI, CathWorks, Siemens AG, Philips, and ReCor Medical; and travel expenses/meals from Medtronic plc, Boston Scientific Corporation, Funding Information: Abbott Vascular, Abiomed, CSI, CathWorks, Siemens, Philips, ReCor Medical, Chiesi USA, OpSens, Inc, ZOLL, and Regeneron Pharmaceuticals, Inc. Dr Mehran reported receiving grants and/or research institutional funding from AstraZeneca plc, Medtronic plc, Janssen Pharmaceutica, Bayer AG, Beth Israel Deaconess, CSL Behring, DSI, Novartis International AG, OrbusNeich, Novartis Pharmaceuticals, Sanofi/ Regeneron, and Boston Scientific Corporation; personal fees from Sanofi SA, Medscape/WebMD, Roivant Services, Siemens Medical Solutions, Boston Scientific Corporation, Janssen Scientific Affairs, and Medtelligence (Janssen Scientific Affairs); grants, personal fees, and other support from Abbott Laboratories; grants and other support from Bristol-Myers Squibb; personal fees to her spouse from Abiomed and The Medicines Company; consulting relationships with Idorsia Pharmaceuticals Ltd, Regeneron Pharmaceuticals, Inc, and Spectranetics/Philips/Volcano Corp; participation in a data safety and monitoring board for Watermark Research Partners; service as an associate editor to the American College of Cardiology and the American Medical Association; and equity in Claret Medical and Elixir Medical Corporation outside of the submitted work. Dr Navar reported receiving funding for research to her institution from Amgen, Inc, Janssen Pharmaceutica, Amarin Corporation, Sanofi SA, and Regeneron Pharmaceuticals, Inc, and honoraria and consulting fees from Amgen, Inc, AstraZeneca plc, Janssen Pharmaceutica, Esperion Therapeutics, Inc, Amarin Corporation, Sanofi SA, Regeneron Pharmaceuticals, Inc, Novo Nordisk A/S, Novartis Pharmaceuticals, The Medicines Company, New Amsterdam, Cerner Corporation, 89bio, Inc, and Pfizer, Inc.",

year = "2020",

month = oct,

doi = "10.1001/jamacardio.2020.2493",

language = "English",

volume = "5",

pages = "1163--1164",

journal = "JAMA Cardiology",

issn = "2380-6583",

publisher = "American Medical Association",

number = "10",

}

TY - JOUR

T1 - Heroism in the Face of the COVID-19 Pandemic

AU - Bonow, Robert O.

AU - Kirtane, Ajay J.

AU - Mehran, Roxana

AU - Navar, Ann Marie

N1 - Funding Information: reported receiving institutional funding to Columbia University and/or the Cardiovascular Research Foundation for research, speaking engagements, and/or consulting from Medtronic plc, Boston Scientific Corporation, Abbott Vascular, Abiomed, CSI, CathWorks, Siemens AG, Philips, and ReCor Medical; and travel expenses/meals from Medtronic plc, Boston Scientific Corporation, Funding Information: Abbott Vascular, Abiomed, CSI, CathWorks, Siemens, Philips, ReCor Medical, Chiesi USA, OpSens, Inc, ZOLL, and Regeneron Pharmaceuticals, Inc. Dr Mehran reported receiving grants and/or research institutional funding from AstraZeneca plc, Medtronic plc, Janssen Pharmaceutica, Bayer AG, Beth Israel Deaconess, CSL Behring, DSI, Novartis International AG, OrbusNeich, Novartis Pharmaceuticals, Sanofi/ Regeneron, and Boston Scientific Corporation; personal fees from Sanofi SA, Medscape/WebMD, Roivant Services, Siemens Medical Solutions, Boston Scientific Corporation, Janssen Scientific Affairs, and Medtelligence (Janssen Scientific Affairs); grants, personal fees, and other support from Abbott Laboratories; grants and other support from Bristol-Myers Squibb; personal fees to her spouse from Abiomed and The Medicines Company; consulting relationships with Idorsia Pharmaceuticals Ltd, Regeneron Pharmaceuticals, Inc, and Spectranetics/Philips/Volcano Corp; participation in a data safety and monitoring board for Watermark Research Partners; service as an associate editor to the American College of Cardiology and the American Medical Association; and equity in Claret Medical and Elixir Medical Corporation outside of the submitted work. Dr Navar reported receiving funding for research to her institution from Amgen, Inc, Janssen Pharmaceutica, Amarin Corporation, Sanofi SA, and Regeneron Pharmaceuticals, Inc, and honoraria and consulting fees from Amgen, Inc, AstraZeneca plc, Janssen Pharmaceutica, Esperion Therapeutics, Inc, Amarin Corporation, Sanofi SA, Regeneron Pharmaceuticals, Inc, Novo Nordisk A/S, Novartis Pharmaceuticals, The Medicines Company, New Amsterdam, Cerner Corporation, 89bio, Inc, and Pfizer, Inc.

PY - 2020/10

Y1 - 2020/10

UR - https://www.scopus.com/pages/publications/85086716449

U2 - 10.1001/jamacardio.2020.2493

DO - 10.1001/jamacardio.2020.2493

M3 - Editorial

C2 - 32558909

AN - SCOPUS:85086716449

SN - 2380-6583

VL - 5

SP - 1163

EP - 1164

JO - JAMA Cardiology

JF - JAMA Cardiology

IS - 10

ER -